The $52.7M award adds near-term revenue visibility through December 2026. Monitor for additional option exercises or international orders, but the stock may already price in routine government contract flow. No earnings or guidance changes accompany this filing.
EBS drugs
EBS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $8.46entry
- T+1 · 5mo ago −0.95%α −1.72% · $8.38
- T+5 · 4mo ago −3.31%α −4.70% · $8.18
- T+20 · 4mo ago −14.18%α −13.90% · $7.26
- T+60 · 8w ago −20.09%α −24.46% · $6.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Emergent BioSolutions received a $52.7 million contract modification from the U.S. government (ASPR) for ACAM2000 vaccine supply under an existing 10-year contract. Deliveries begin June 2026, with diluent lots by December 2026. This is a material but routine government award, providing near-term revenue visibility.
Key Facts
- Contract modification valued at $52.7 million from ASPR for ACAM2000 vaccine
- Deliveries of doses and ancillaries to begin June 2026; diluent replacement lots by December 2026
- Modification exercises Option Year 7 under existing 10-year contract (75A50119C00071)
- Recent international approvals: Saudi FDA and Singapore HSA expanded ACAM2000 indications for mpox
Financial Impact
$52.7 million contract modification, representing ~12% of current market cap
Risk Factors
- Government contract dependency; budget or policy shifts could impact future awards
- Execution risk on delivery timelines and diluent production
- ACAM2000 safety profile (boxed warning for myocarditis, pericarditis) limits commercial expansion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001367644-26-000068 |
| Document: a06292026acammodpr.htm | 0001367644-26-000068 |
| Document: 0001367644-26-000068-index-headers.html | 0001367644-26-000068 |
| Document: 0001367644-26-000068-index.html | 0001367644-26-000068 |
| Document: 0001367644-26-000068.txt | 0001367644-26-000068 |
Track record
23 reports on EBS
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +14.89% at T+20 after the Apr 29, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
- Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
- Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
- Jun 29, 202620w ago 8-K Bullish 5/10 Viewing Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
- Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers